Central Blood Pressure Over 24 Hours (ABPM) and Left Ventricular Mass

This study has been completed.
Austrian Society of Hypertension
Government of lower Austria and European Funds for Regional Development (WST3-T-81/015-2008)
I.E.M. (Stolberg, Germany)
Information provided by (Responsible Party):
Thomas Weber, Klinikum Wels-Grieskirchen
ClinicalTrials.gov Identifier:
First received: January 18, 2011
Last updated: March 31, 2015
Last verified: March 2015

The investigators aim to investigate whether central systolic blood pressure, as measured during regular 24 hour ambulatory blood pressure monitoring (ABPM), is a better predictor of left ventricular mass than peripheral systolic blood pressure during ABPM.

Condition Intervention
Suspected Arterial Hypertension
Other: no intervention performed

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Central Blood Pressure Over 24 Hours (ABPM) and Left Ventricular Mas

Resource links provided by NLM:

Further study details as provided by Klinikum Wels-Grieskirchen:

Primary Outcome Measures:
  • Left ventricular mass (m-mode echocardiography) [ Time Frame: measured within 4 weeks from ABPM ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • urine albumine / creatinine ratio [ Time Frame: measured within 2 weeks from ABPM but before antihypertensive treatment is started ] [ Designated as safety issue: No ]

Enrollment: 350
Study Start Date: January 2011
Study Completion Date: March 2015
Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
untreated persons with suspected hypertension Other: no intervention performed
no intervention is performed

Detailed Description:

It seems obvious that central blood pressures are pathophysiologically more relevant than peripheral blood pressures for the pathogenesis of cardiovascular disease: it is central systolic pressure (cSBP) against the heart ejects (afterload), and it is central pulse pressure (cPP) that distends the large elastic arteries. Indeed, cSBP and cPP have been associated more closely with left ventricular hypertrophy and carotid atherosclerosis as markers of hypertensive end-organ damage than brachial pressures in various populations. However, in these studies office blood pressure measurements have been used. As ABPM measurements per se show a closer association with hypertensive end-organ damage than office measurements, and as the investigators have recently developed and validated a novel algorithm (ARCSolver) to calculate central blood pressures from peripheral waveforms, the investigators speculate that cSBP measured during ABPM may be the best predictor of left ventricular mass.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

community sample


Inclusion Criteria:

  • 18 years of age,
  • no intake of antihypertensive medications
  • should have an indication for ABPM (suspected arterial hypertension)

Exclusion Criteria:

  • no written informed consent
  • left ventricular hypertrophy due to other reasons than hypertension (hypertrophic cardiomyopathy, infiltrative cardiomyopathy, valvular heart disease, congenital heart disease)
  • inability to provide adequate echocardiographic readings
  • segmental contraction abnormalities of the left ventricle
  • contraindications for ABPM (lymphedema both arms)
  • other rhythm than stable sinus rhythm
  • unstable clinical condition, including recent severe infections
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01278732

Cardiology Department, Klinikum Wels-Grieskirchen
Wels, Upper Austria, Austria, 4600
Cardiology Department, University of Graz
Graz, Austria
Cardiology Department, University of Lübeck
Lübeck, Germany
Sotiria Hospital 3rd Department of Internal Medicine
Athens, Greece
Department of Medical and Surgical Sciences, University of Brescia
Brescia, Italy
Clinica Medica, Hospitalo San Gerardo
Monza, Italy
Unit of Internal Medicine, Angiology and Arteriosclerosis, University of Perugia
Perugia, Italy
Hospital de Sagunto
Puerto de Sagunto, Spain, E - 46520
University of Basel
Basel, Switzerland
United Kingdom
Clinical pharmacology unit, University of Cambridge
Cambridge, United Kingdom
Sponsors and Collaborators
Klinikum Wels-Grieskirchen
Austrian Society of Hypertension
Government of lower Austria and European Funds for Regional Development (WST3-T-81/015-2008)
I.E.M. (Stolberg, Germany)
Principal Investigator: Thomas Weber, MD, associate professor Cardiology Department, Klinikum Wels-Grieskirchen, Austria
  More Information

No publications provided

Responsible Party: Thomas Weber, PD Dr. Thomas Weber, Klinikum Wels-Grieskirchen
ClinicalTrials.gov Identifier: NCT01278732     History of Changes
Other Study ID Numbers: EK D-4-10
Study First Received: January 18, 2011
Last Updated: March 31, 2015
Health Authority: Austria: Federal Ministry for Health

Keywords provided by Klinikum Wels-Grieskirchen:
arterial hypertension

Additional relevant MeSH terms:
Cardiovascular Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on October 09, 2015